SAKL yields 25000.00% · ABBV yields 3.09%● Live data
📍 SAKL pulled ahead of the other in Year 1
Combined, SAKL + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SAKL + ABBV for your $10,000?
Sack Lunch Productions, Inc., together with its subsidiaries, engages in the event and film production businesses worldwide. The company operates through three segments: Events, Salons, and Other. The Events segment produces branded events under the Color Me Rad, The Dirty Dash, Lantern Fest, Slide the City, and Trike Riot trademarked names; and franchises its branded events to third parties under agreements with various franchisees. The Salons segment operates health and beauty salons. This segment operates through a network of two Aveda lifestyle salons; and an Aveda retail store. The Other segment distributes films; provides assisting services in the development and production of film products; and acquires, leases, and sells commercial and residential properties. The company was formerly known as Nexia Holdings, Inc. and changed its name to Sack Lunch Productions, Inc. in April 2015. Sack Lunch Productions, Inc. was incorporated in 1987 and is headquartered in Salt Lake City, Utah.
Full SAKL Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.